Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? (Q45921489)

17 December 2017

title

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? (English)

1 reference

17 December 2017

author

Elena Tamborini

4

1 reference

17 December 2017

Paolo Giovanni Casali

6

1 reference

17 December 2017

Marco Fiore

7

1 reference

17 December 2017

Alessandro Gronchi

9

1 reference

17 December 2017

author name string

C Mussi

1

1 reference

17 December 2017

U Ronellenfitsch

2

1 reference

17 December 2017

J Jakob

3

1 reference

17 December 2017

P Reichardt

5

1 reference

17 December 2017

P Hohenberger

8

1 reference

17 December 2017

publication date

23 July 2009

1 reference

17 December 2017

published in

Annals of Oncology

1 reference

17 December 2017

volume

21

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

403-408

1 reference

17 December 2017

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Response evaluation of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP310

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP310

1 reference

17 December 2017

1 reference

17 December 2017